

Patient or Provider



Pericarditis Report to SAEFVIC

Pericarditis (AESI) & COVID-19 mRNA Vaccine Decision Guide

Which dose?

Dose 1

Dose 2

ViCSIS Referral (non-urgent) as have completed primary vaccine course

Info Evaluation

Abnormal troponin = myocarditis pathway

Abnormal ECG or bloods or echo or CXR

Gather investigations / information

Chest pain with normal investigations (ECG/Echo/Bloods/CXR)

Investigations not available or not done

Brighton Level 1-3

Brighton Level 5

Brighton Level 4

Waiting Period / ViCSIS

Minimum 6 weeks from initial chest pain AND symptoms have resolved

VicSIS referral recommended

VicSIS referral NOT recommended unless significant concerns

Minimum 6 weeks from initial chest pain AND symptoms have resolved

VicSIS referral optional

Minimum 6 weeks from initial chest pain AND symptoms have resolved

Dose 2 Decision

> 60 yo (any sex)

Female 12-59 yo

Male 25-59 yo

Male 12-24 yo

All age groups

> 60 yo (any sex)

Female 12-59 yo

Male 25-59 yo

Male 12-24 yo

Proceed with 2nd dose AZ

For >30 yo, consider dose 2 mRNA vs AZ
For <30yo, consider alternative vaccine*

Do not proceed with vaccination at this time.
Individual risk & benefit discussion*

Proceed with 2nd dose mRNA vaccine

Proceed with 2nd dose AZ OR 2nd dose mRNA

Proceed with dose 2 mRNA

Proceed with dose 2 mRNA after discussion w patient

Do not proceed with vaccination at this time.
Individual risk & benefit discussion*

* AZ not licensed for <18yo